Serevent Medicaid Study Could Offer Insight Into African-American Risk

A Serevent Medicaid claims study could provide data on ethnic risk differences for respiratory-related severe adverse events with long-acting beta agonist bronchodilators, GlaxoSmithKline said during a July 13 meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee